A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Yoon Hee | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Kim, Jun Suk | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Kim, Bong-Seog | - |
dc.contributor.author | Cho, Sang-Hee | - |
dc.contributor.author | Chung, Ik Joo | - |
dc.contributor.author | Song, Eun-Kee | - |
dc.contributor.author | Yim, Chang-Yeol | - |
dc.contributor.author | Baek, Jin Ho | - |
dc.contributor.author | Jeung, Hei-Cheul | - |
dc.contributor.author | Hong, Young Seon | - |
dc.contributor.author | Yang, Sung Hyun | - |
dc.contributor.author | Kang, Hye Jin | - |
dc.date.accessioned | 2021-09-06T14:01:44Z | - |
dc.date.available | 2021-09-06T14:01:44Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2012-11 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/107136 | - |
dc.description.abstract | Background Surgery alone is no longer an adequate standard of care for patients with resectable gastric cancer. Thus, research efforts should focus on which regimens are the most effective for patients with recurrent gastric cancer after combined treatment with surgery and perioperative or adjuvant chemotherapy. Methods Patients with histologically confirmed and measurable advanced gastric cancer who showed a relapse even after fluoropyrimidine and/or cisplatin-based adjuvant chemotherapy received docetaxel (35 mg/m(2)) intravenously on day 1 and 8 plus oxaliplatin (100 mg/m(2)) intravenously on day 1 every 3 weeks until disease progression or unacceptable toxicity. Results A total of 34 patients with relapsed advanced gastric cancer who had received adjuvant chemotherapy with fluoropyrimidine and/or cisplatin for a median of 6 months (range, 1-48 months) were enrolled in this trial; 22 (64.7 %) patients had been exposed to both agents. Their median age was 58 years (range, 50-68 years). The overall response rate was 55.9 % (95 % confidence interval (CI), 38.3-73.5 %), including 1 complete response and 18 partial responses. At a median follow-up duration of 28.5 months (range, 9.2-50.7 months), the median progression-free survival for all patients was 5.3 months (95 % CI, 4.4-6.1 months) and the median overall survival was 13.8 months (95 % CI, 11.1-16.4 months). The most common grade 3 or 4 hematologic and nonhematologic toxicities were neutropenia (47.1 %) and diarrhea (17.6 %), respectively. Five patients (14.7 %) experienced febrile neutropenia. Conclusions Docetaxel and oxaliplatin combination chemotherapy was active and tolerable in patients with recurrent gastric cancer after fluoropyrimidine and/or cisplatin-based adjuvant chemotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | ADVANCED ESOPHAGOGASTRIC CANCER | - |
dc.subject | CELL LUNG-CANCER | - |
dc.subject | 1ST-LINE TREATMENT | - |
dc.subject | PLUS CISPLATIN | - |
dc.subject | ONCOLOGY GROUP | - |
dc.subject | FOLINIC ACID | - |
dc.subject | IN-VITRO | - |
dc.subject | TRIAL | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | THERAPY | - |
dc.title | A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.contributor.affiliatedAuthor | Kim, Jun Suk | - |
dc.identifier.doi | 10.1007/s00280-012-1956-1 | - |
dc.identifier.scopusid | 2-s2.0-84871210725 | - |
dc.identifier.wosid | 000310537600005 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.70, no.5, pp.665 - 672 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 70 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 665 | - |
dc.citation.endPage | 672 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ADVANCED ESOPHAGOGASTRIC CANCER | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | PLUS CISPLATIN | - |
dc.subject.keywordPlus | ONCOLOGY GROUP | - |
dc.subject.keywordPlus | FOLINIC ACID | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Stomach neoplasm | - |
dc.subject.keywordAuthor | Recurrence | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.